- Home
- LILAK vs PTGX Comparison
LILAK vs PTGX Comparison
Compare LILAK & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | PTGX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 5.2B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | LILAK | PTGX |
|---|---|---|
| Price | $7.85 | $98.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $8.20 | ★ $106.67 |
| AVG Volume (30 Days) | ★ 927.4K | 709.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | $867.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $39.60 |
| 52 Week High | $9.13 | $105.69 |
Technical Indicators
Market Signals| Indicator | LILAK | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 62.54 |
| Support Level | $7.53 | $76.63 |
| Resistance Level | $8.44 | N/A |
| Average True Range (ATR) | 0.30 | 4.83 |
| MACD | 0.01 | 0.45 |
| Stochastic Oscillator | 62.00 | 61.78 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.